Provided by Tiger Trade Technology Pte. Ltd.

JUNSHI BIO

19.040
+0.4102.20%
Volume:3.85M
Turnover:74.16M
Market Cap:19.55B
PE:-21.89
High:19.700
Open:18.900
Low:18.790
Close:18.630
52wk High:38.640
52wk Low:15.250
Shares:1.03B
HK Float Shares:260.00M
Volume Ratio:0.88
T/O Rate:1.48%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.870
ROE:-13.49%
ROA:-3.70%
PB:2.84
PE(LYR):-21.89
PS:6.15

Loading ...

Junshi Bio Turns Profitable as H1 2026 Revenue Leaps 45% to RMB1.70 Billion on Strong TUOYI® Momentum

Bulletin Express
·
Yesterday

Junshi Biosciences Reports First-Half Net Profit of RMB21.66 Million, Reversing Year-Earlier Loss

Stock News
·
7 hours ago

Junshi Bio Terminates 2026 A-Share Employee Stock Ownership Scheme

Bulletin Express
·
Yesterday

Shanghai Junshi Biosciences Return to Profit in H1

MT Newswires Live
·
Yesterday

Junshi Biosciences Swings to Profit in First-Half Results

Stock News
·
Yesterday

Junshi Biosciences Raises 700 Million Yuan Through Tech Innovation Bond Issuance

Stock News
·
Aug 21

Shareholder Offloads Nearly 7 Billion Yuan in Precision-Timed Selloff, Stake Drops to 3.79%

Deep News
·
Aug 21

JUNSHI BIO Sets 26 August 2026 Board Meeting to Review 1H 2026 Results

Bulletin Express
·
Aug 12

Junshi Biosciences Shareholder Cuts Stake

MT Newswires Live
·
Aug 11

JUNSHI BIO Shareholder He Ming Completes Sale of 882,600 Shares, Fulfilling Reduction Plan

Stock News
·
Aug 10

Junshi Biosciences Completes 300 Million Yuan Second Tranche Bond Issue

MT Newswires Live
·
Jul 23

Shanghai Junshi's Toripalimab Supplemental Application Accepted in China

MT Newswires Live
·
Jul 22

Shanghai Junshi Biosciences Gets NMPA Acceptance Notice of Supplemental Application for Toripalimab

Reuters
·
Jul 22

Shanghai Junshi Biosciences - Acceptance of Supplemental Application for Toripalimab in Combination with Chemotherapy as Perioperative Treatment

THOMSON REUTERS
·
Jul 21

Shanghai Junshi Biosciences - Acceptance Notice Issued by Nmpa China

THOMSON REUTERS
·
Jul 21

Zhongou Fund's Ge Lan Q2 Report Revealed: Junshi Bio Enters Top Holdings, Kelun Pharma Sees Major Increase

Deep News
·
Jul 21

HK Movers | Biomedical Stocks Rally; REMEGEN, WUXI XDC and KEYMED BIO-B Surge Over 8%

Tiger Newspress
·
Jul 20

JUNSHI BIO Shares Surge Over 5% on Inclusion of Junmaikang® in National Essential Drug List

Stock News
·
Jul 10

JUNSHI BIO Seeks Shareholders’ Nod for 10% H-Share Buyback Mandate

Bulletin Express
·
Jul 08

Junshi Biosciences to Seek H-Share Repurchase Mandate at 27 July 2026 EGM

Bulletin Express
·
Jul 08